Previous 10 | Next 10 |
REDWOOD CITY, Calif. and JUPITER, Fla., June 01, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metabolizing enzy...
REDWOOD CITY, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment conferences: 17 th Annual Craig-Hallum Institutional Investor Conference being held in a on...
Many synthetic biology companies have gone all in on business models that prioritize research and development (R&D) revenue. On one hand, collaboration deals grab headlines and create hype, which can be cashed in for venture capital or goodwill with investors. On the other hand, collaboratio...
REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare Conference on Monday, May 18 at 9:10 a.m. Eastern time (6:10 a.m. Pacific time). A live we...
Codexis, Inc. (CDXS) Q1 2020 Earnings Conference Call May 07, 2020 04:30 PM ET Company Participants Bruce Voss - Investor Relations John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Conference Call Participants Brandon Couillard - Jef...
Image source: The Motley Fool. Codexis (NASDAQ: CDXS) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading
Codexis (NASDAQ: CDXS ): Q1 Non-GAAP EPS of -$0.09 beats by $0.03 ; GAAP EPS of -$0.13 beats by $0.03 . More news on: Codexis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
R&D revenue increased 26% to $9.6 million fueled by the Novartis and Takeda strategic collaborations Withdraws 2020 financial guidance due to uncertainty of COVID-19 potential impact Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif., May 07, 202...
REDWOOD CITY, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver ® platform technology transfer and license agreement with N...
REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Develop...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...